Survey and Recommendations on the Use of P-Values Driving Decisions in Nonclinical Pharmaceutical Applications

aJanssen R&D, Raritan, NJ; bPrinceton Data Analytics, Bridgewater, NJ; cRutgers University, New Brunswick, NJ; dPfizer Inc, Cambridge, MA; eJanssen R&D, Beerse, Belgium; fCMCStats, Wadsworth, Il; gPfizer Inc, Groton, CT; hIncyte Corp, Wilmington, DE; iPfizer Inc, Andover, MA; jAmgen Inc, Thousand Oaks, CA; kAstraZeneca, Gaithersburg, MD; lJanssen R&D, Prague, Czechia; mPDQ Research & Consulting, Birdsboro, PA; nRoche Diagnostics Gmbh, Penzberg, Germany; oCMC Sciences LLC, Germantown, MD; pPfizer Inc, Collegeville, PA; qCovance by Labcorp, Huntingdon, UK